-
公开(公告)号：EP1902049A2
公开(公告)日：2008-03-26
申请号：EP06762404.9
申请日：2006-06-22
发明人： HILLISCH, Alexander , BOTHE, Ulrich , KAUFMANN, Guenter , SOBEK, Lothar , FUHRMANN, Ulrike , DROESCHER, Peter , SCHMEES, Norbert , SCHWEDE, Wolfgang , MOELLER, Carsten , SCHMIDT, Anja
IPC分类号： C07D413/12 , C07D265/02 , A61K31/536 , A61P5/34
CPC分类号： C07D413/12 , C07D265/02
摘要： The present invention relates to non-steroidal progesterone receptor modulators of the general formula (I), a process for their preparation, the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical compositions comprising these compounds. The compounds according to the invention are suitable for the therapy and prophylaxis of gynaecological disorders such as endometriosis, leiomyomas of the uterus, dysfunctional (bleeding )and dysmenorrhoea, and for the therapy and prophylaxis of hormone-dependent tumours and for use for female fertility control and for hormone replacement therapy.
-
2.发明公开SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11 -Ý4-(HYDROXYACETYL) PHENYL¨-19-NOR-17 -PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN 审中-公开按顺序处理的20,20,21,21五氟-17-羟基-11--Ý4-（羟基乙酰基）苯基-19-降-17-孕-4,9-二烯-3-酮和一种或多种孕激素为 妇科疾病治疗
公开(公告)号：EP2285383A2
公开(公告)日：2011-02-23
申请号：EP09745520.8
申请日：2009-05-07
IPC分类号： A61K31/567 , A61P5/34 , A61P5/36
CPC分类号： A61K31/567 , A61K31/57 , A61K31/585 , A61K2300/00
摘要： The invention relates to a treatment regime and to combination preparations of 20,20,21,21,21 -pentafluoro-17-hydroxy-11 ß-[4- (hydroxyacetyl)phenyl]-19-nor-17α-pregna-4,9-diene-3-one of formula (I). Said invention relates to, in particular, a sequential regime for treating gynaecological diseases in which, in a first phase, the above-mentioned progesterone antagonist is administered and, in a second phase, a progestational hormone is administered.
-
公开(公告)号：EP2081951B1
公开(公告)日：2010-04-21
申请号：EP07819866.0
申请日：2007-11-14
发明人： FUHRMANN, Ulrike , SCHMIDT, Anja , CLEVE, Arwed , PETROV, Orlin , GARKE, Gunnar , PRUEHS, Stefan , BRUDNY-KLOEPPEL, Margarete , ROTTMANN, Antje , HASSELMANN, Rainer , SCHULTZE-MOSGAU, Marcus , MOELLER, Carsten
IPC分类号： C07J1/00 , C07J21/00 , C07J51/00 , A61K31/567 , A61P5/36
CPC分类号： C07J1/0081 , C07J21/006 , C07J51/00
-
公开(公告)号：EP2081951A1
公开(公告)日：2009-07-29
申请号：EP07819866.0
申请日：2007-11-14
发明人： FUHRMANN, Ulrike , SCHMIDT, Anja , CLEVE, Arwed , PETROV, Orlin , GARKE, Gunnar , PRUEHS, Stefan , BRUDNY-KLOEPPEL, Margarete , ROTTMANN, Antje , HASSELMANN, Rainer , SCHULTZE-MOSGAU, Marcus , MOELLER, Carsten
IPC分类号： C07J1/00 , C07J21/00 , C07J51/00 , A61K31/567 , A61P5/36
CPC分类号： C07J1/0081 , C07J21/006 , C07J51/00
摘要： The present invention relates to progesterone receptor antagonists of general formula I: in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.
-
5.发明授权18-METHYL-19-NOR-17-PREGN-4-EN-21,17-CARBOLACTONE, SOWIE DIESE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE 有权18-甲基-19-去甲-17-孕-4-烯21,17羧内酯，和药物制剂含有它们
公开(公告)号：EP1831240B8
公开(公告)日：2010-02-17
申请号：EP05850392.1
申请日：2005-12-30
发明人： BOHLMANN, Rolf , BITTLER, Dieter , KUENZER, Hermann , ESPERLING, Peter , MUHN, Hans-Peter , FRITZEMEIER, Karl-Heinrich , FUHRMANN, Ulrike , PRELLE, Katja , BORDEN (FRÜHER KURZ), Steffen
IPC分类号： C07J53/00 , A61K31/585 , A61P5/34
CPC分类号： C07J21/00 , C07J53/008
-
6.发明公开
公开(公告)号：EP2131825A1
公开(公告)日：2009-12-16
申请号：EP08717238.3
申请日：2008-02-28
发明人： MOELLER, Carsten , KAUFMANN-REICHE, Ulrike , SCHMIDT, Anja , FUHRMANN, Ulrike , FISCHER, Oliver-Martin
IPC分类号： A61K31/00 , A61K31/585 , A61P15/00
CPC分类号： A61K31/00 , A61K31/585
摘要： The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endometriosis, which has a more favorable effectiveness profile and/or profile of side effects than previously available treatment therapies. With a mineralcorticoid receptor antagonist, endometriosis can be lastingly treated without resulting in a loss of bone mass.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.012 秒)
